1. Turkey Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Deva Holding A.S.

Deva Holding A.S.

BBIST:DEVA
71.65
TRY
-1.00
(-1.38%)
-4.17EPS
14.33BMarket Cap
Deva Holding A.S.
BIST:DEVA
(Istanbul Exchange)

Recent

price

71.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TRY
2.46
2.25
2.1
2.09
2.34
2.88
3.44
4
5.2
6.87
9.32
11.65
43.56
81.78
101.16
96.22
108.31
Revenue per Share
-0.01
-0.09
0.17
0.12
0.04
0.24
0.3
0.46
0.68
1.43
3.26
5.85
4.25
24.44
0.45
-4.03
-4.17
Basic EPS, GAAP
-0.33
-0.4
-0.35
-0.08
-0.18
0.07
0.44
-0.08
-0.14
1.13
1.45
3.33
-0.21
17.33
28.24
14.6
-9.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.27
0.49
1.78
2.01
3.02
- -
- -
Dividend per Share
1.77
1.72
1.89
2.01
2.06
2.27
2.56
3.03
3.73
5.15
8.17
13.64
57.65
106.71
136.19
131.59
157.63
Book Value per Share
1.48
1.38
1.47
1.45
1.29
1.34
1.46
1.82
2.36
3.66
6.73
11.86
39.69
80.2
97.63
90.54
109.47
Tangible Book Value per Share
157
180
200
200
200
200
200
200
200
200
200
200
200
200
200
200
202
Basic Weighted Avg Shares
386
405
420
418
468
576
688
800
1,041
1,374
1,863
2,330
8,713
16,359
20,234
19,246
21,882
Sales/Revenue/Turnover
1.77
1.26
14.94
9.16
9
15.6
16.66
17.26
24
29.1
33.99
36.09
1.27
9.71
10.91
0.05
5.59
Operating Margin (%)
17
19
23
25
25
27
27
31
35
46
60
79
643
982
1,422
1,557
1,598
Depreciation Expense
-2
-16
34
25
9
48
60
93
136
286
651
1,170
851
4,888
91
-807
-842
Net Income, GAAP
- -
- -
16.9
- -
- -
7.9
16.18
2.15
12.57
- -
- -
- -
30.1
- -
81.21
- -
241.15
Effective Tax Rate (%)
-0.42
-3.86
8.16
5.88
1.86
8.27
8.76
11.56
13.1
20.82
34.96
50.21
9.77
29.88
0.45
-4.19
-3.85
Profit Margin (%)
96
87
81
177
150
12
204
203
378
571
962
1,735
3,030
6,638
6,081
6,553
10,013
Working Capital
- -
74
54
182
197
49
226
191
285
353
380
620
833
551
1,132
679
2,104
LT Debt
340
344
379
403
412
453
513
605
746
1,031
1,634
2,728
11,530
21,344
27,240
26,320
31,530
Total Equity
- -
- -
8.72
- -
- -
10.79
11.57
14.36
18.94
- -
- -
- -
6.45
- -
2.12
- -
-7.83
Return on Invested Capital (%)
- -
- -
15.37
- -
- -
15.89
16.38
14.97
18.31
- -
- -
- -
15.61
- -
2.49
- -
-12.69
Return on Capital (%)
-0.5
-4.57
9.47
6.3
2.14
11.02
12.49
16.56
20.18
32.19
48.89
53.65
11.94
29.74
0.37
-3.01
-2.99
Return on Common Equity (%)

Capital Structure

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,303
4,520
4,165
LT Borrowings
524
1,965
1,957
LT Finance Leases
156
189
147
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
200
200
200
Market Capitalization
12,541
12,011
14,331

Working Capital

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
16,626
18,166
19,100
Cash, Cash Equivalents & STI
3,593
4,432
3,570
Accounts Receivable, Net
7,058
7,153
7,695
Inventories
5,426
6,052
7,188
Total Current Liabilities
10,073
9,105
9,087
Payables & Accruals
- -
- -
- -
ST Debt
5,303
4,520
4,165
Deferred Revenue
- -
- -
- -

Growth Rates

TRY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
65.01%
99.79%
-3.38%
Free Cash Flow
-856.22%
-1,632.35%
-48.31%
Net Income, GAAP
-19.48%
-111.92%
-988.12%
Sales/Revenue/Turnover
53.89%
81.1%
-4.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,948
3,817
4,877
4,490
20,234
2025
5,479
5,540
4,474
5,491
19,246
2026
5,912
6,005
- -
- -
- -

Quarterly Earnings Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.62
5.86
-1.78
-0.8
0.45
2025
0.12
3.3
-0.1
-6.72
-4.03
2026
-0.45
3.07
- -
- -
- -

Quarterly Dividends Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.2
0.14
3.02
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Deva Holding A.S. (DEVA.IS) is a diversified Turkish conglomerate engaged in pharmaceuticals, healthcare, real estate development, energy, and information technology sectors. The company manufactures and markets a broad portfolio of pharmaceutical products including generic drugs, branded generics, oncology medications, and over-the-counter remedies under its own brands; it also provides contract manufacturing services for third-party pharmaceutical firms, operates hospitals and healthcare facilities, develops residential and commercial real estate projects, generates renewable energy through solar and wind power plants, and offers IT solutions such as software development and digital transformation services. Deva Holding serves domestic markets in Turkey as well as international customers across Europe, the Middle East, and Central Asia, with manufacturing facilities compliant with EU-GMP standards. Founded in 1958 and headquartered in Istanbul, Turkey, the company has expanded through subsidiaries focused on each business segment without a listed parent entity. In recent developments within the last two years, Deva Holding completed a strategic acquisition of a leading regional oncology drug portfolio to bolster its pharmaceutical offerings, announced a major funding round for expanding renewable energy capacity by 200 MW, and launched new digital health platforms integrating telemedicine with its hospital network amid post-pandemic operational shifts.